검색결과 : 10건
| No. | Article |
|---|---|
| 1 |
CTLA-4 blockade drives loss of T-reg stability in glycolysis-low tumours Zappasodi R, Serganova I, Cohen IJ, Maeda M, Shindo M, Senbabaoglu Y, Watson MJ, Leftin A, Maniyar R, Verma S, Lubin M, Ko M, Mane MM, Zhong H, Liu CL, Ghosh A, Abu-Akeel M, Ackerstaff E, Koutcher JA, Ho PC, Delgoffe GM, Blasberg R, Wolchok JD, Merghoub T Nature, 591(7851), 652, 2021 |
| 2 |
Cancer immunotherapy using checkpoint blockade Ribas A, Wolchok JD Science, 359(6382), 1350, 2018 |
| 3 |
Chromatin states define tumour-specific T cell dysfunction and reprogramming Philip M, Fairchild L, Sun L, Horste EL, Amara SC, Shakiba M, Scott AC, Viale A, Lauer P, Erghoub TM, Hellmann MD, Wolchok JD, Leslie CS, Schietinger A Nature, 545(7655), 452, 2017 |
| 4 |
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu XW, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ Nature, 545(7652), 60, 2017 |
| 5 |
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer Balachandran VP, Luksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, Wells DK, Cary CIO, Grbovic-Huezo O, Attiyeh M, Medina B, Zhang J, Loo J, Saglimbeni J, Abu-Akeel M, Zappasodi R, Riaz N, Smoragiewicz M, Kelley ZL, Basturk O, Gonen M, Levine AJ, Allen PJ, Fearon DT, Merad M, Gnjatic S, Iacobuzio-Donahue CA, Wolchok JD, DeMatteo RP, Chan TA, Greenbaum BD, Merghoub T, Leach SD Nature, 551(7681), 512, 2017 |
| 6 |
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy Luksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, Rizvi NA, Merghoub T, Levine AJ, Chan TA, Wolchok JD, Greenbaum BD Nature, 551(7681), 517, 2017 |
| 7 |
Overcoming resistance to checkpoint blockade therapy by targeting PI3K gamma in myeloid cells De Henau O, Rausch M, Winkler D, Campesato LF, Liu CL, Hirschhorn-Cymerman D, Budhu S, Ghosh A, Pink M, Tchaicha J, Douglas M, Tibbitts T, Sharma S, Proctor J, Kosmider N, White K, Stern H, Soglia J, Adams J, Palombella VJ, McGovern K, Kutok JL, Wolchok JD, Merghoub T Nature, 539(7629), 443, 2016 |
| 8 |
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TBK, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao DN, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C Science, 351(6280), 1463, 2016 |
| 9 |
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan JD, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA Science, 348(6230), 124, 2015 |
| 10 |
CANCER Antitumour immunity gets a boost Wolchok JD, Chan TA Nature, 515(7528), 496, 2014 |